Continuing Research and Development Activities
First written in FY2017-Q1. 19 of 29 entries say "Restated". Latest entry: FY2026.
41 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥21,376 million for the Group as a whole.」
R&D expenses increased from ¥17,578 million in the previous fiscal year to ¥21,376 million. The company also reported specific progress, including the operation of the second analysis building in Toyama, data-driven research, microbial control and development of nucleic-acid drug candidates. - 2026-05-15AdvancedFinancial results presentation materials
「Research and development expenses are trending upward in Functional Materials, led by semiconductors, and in agricultural chemicals.」
Research and development expenses are set at ¥21.4 billion for fiscal 2025 and ¥24.7 billion for fiscal 2026, indicating an upward trend in investment in semiconductor-focused Functional Materials and agricultural chemicals. The aggregation method was changed from fiscal 2025. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the six-month consolidated accounting period were ¥10,428 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated accounting period.」
The company recorded R&D expenses of ¥10,428 million and explained that there had been no material changes in its R&D activities. - FY2025AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥17,578 million for the Group as a whole.」
R&D expenses increased from ¥17,334 million in the previous fiscal year to ¥17,578 million. The company also reported progress in developing new agricultural chemical products, semiconductor and display materials, data-driven research and microbial control. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the six-month consolidated accounting period were ¥8,510 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated accounting period.」
The company disclosed R&D expenses of ¥8,510 million and explained that there had been no material changes in its R&D activities. - FY2024AdvancedAnnual report
「Regarding an overview of R&D activities in fiscal 2023, the Chemicals segment is expanding proprietary epoxy products based on its own products and technologies for semiconductor packaging and high-frequency circuit-board applications. In the Agricultural Chemicals segment, the company launched Flowable, a fruit-tree product containing fluksumetamide, its original insecticide active ingredient, following products for vegetables, tea and turf.」
R&D expenses totaled ¥17,334 million. The company advanced applications for proprietary epoxy, launched agricultural chemicals for fruit trees, and progressed development of OLED, microLED and EUV materials, as well as nucleic-acid and regenerative-medicine materials. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended December 31 were ¥11,831 million. There were no material changes in the status of the Group's R&D activities during the nine months ended December 31.」
The company recorded R&D expenses of ¥11,831 million and explained that there had been no material changes in its R&D activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the six months ended September 30 were ¥7,937 million. There were no material changes in the status of the Group's R&D activities during the six months ended September 30.」
The company recorded R&D expenses of ¥7,937 million and explained that there had been no material changes in its R&D activities. - FY2023AdvancedAnnual report
「In fiscal 2022, the company launched its new long-term management plan, Atelier2050, and new medium-term management plan, Vista2027. With "Creating firsts for the future" as its corporate slogan, the company is further refining its five existing core technologies—precision organic synthesis, functional polymer design, microparticle control, biological evaluation and optical control—while acquiring new core technologies and pursuing new business areas.」
R&D expenses totaled ¥16,838 million. The company is advancing research into enhancement of its five core technologies, acquisition of new core technologies, materials informatics and the use of microorganisms. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the six months ended September 30 were ¥7,842 million. There were no material changes in the status of the Group's R&D activities during the six months ended September 30.」
The company disclosed R&D expenses of ¥7,842 million and explained that there had been no material changes in its R&D activities. - FY2022AdvancedAnnual report
「This year, the company launched its new long-term management plan, Atelier2050, and new medium-term management plan, Vista2027. With "Creating firsts for the future" as its corporate slogan, the company will further refine its five existing core technologies—precision organic synthesis, functional polymer design, microparticle control, biological evaluation and optical control—while acquiring new core technologies and pursuing new business areas.」
The company recorded R&D expenses of ¥16,023 million and is advancing the enhancement of its five core technologies, acquisition of new technologies and expansion into new business areas, as well as materials informatics and collaboration with external organizations. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended December 31 were ¥11,439 million. There were no material changes in the status of the Group's R&D activities during the nine months ended December 31.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the six months ended September 30 were ¥7,703 million. There were no material changes in the status of the Group's R&D activities during the six months ended September 30.」
The company recorded R&D expenses of ¥7,703 million and explained that there had been no material changes in its R&D activities. - FY2021AdvancedAnnual report
「Regarding progress in fiscal 2020, the Chemicals segment is expanding applications for proprietary epoxy products based on the company's own products and technologies. As part of product development contributing to the SDGs, the number of adoptions of the microbial formulation Venus® Oil Clean has increased, contributing to reductions in industrial waste at food factories. In the Functional Materials segment, covering displays, semiconductors and inorganic materials, development is progressing at the Materials Science Research Institute, which has sites in Funabashi, Sodegaura and Toyama, of high-quality, high-performance grades of existing products and new materials addressing customers' increasingly sophisticated and diverse needs.」
For R&D in fiscal 2020, the company reported expanded product applications, increased adoption of microbial formulations and progress in new-material development. R&D expenses totaled ¥16,459 million. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended December 31 were ¥11,942 million. There were no material changes in the status of the Group's R&D activities during the nine months ended December 31.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the six months ended September 30 were ¥7,844 million. There were no material changes in the status of the Group's R&D activities during the six months ended September 30.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the three months ended June 30 were ¥3,763 million. There were no material changes in the status of the Group's R&D activities during the three months ended June 30.」
The company recorded R&D expenses of ¥3,763 million and explained that there had been no material changes in its R&D activities. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended December 31 were ¥11,983 million. There were no material changes in the status of the Group's R&D activities during the nine months ended December 31.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the six months ended September 30 were ¥8,058 million. There were no material changes in the status of the Group's R&D activities during the six months ended September 30.」
The company disclosed R&D expenses of ¥8,058 million and explained that there had been no material changes in its R&D activities. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the three months ended June 30 were ¥3,932 million. There were no material changes in the status of the Group's R&D activities during the three months ended June 30.」
The company disclosed R&D expenses of ¥3,932 million and explained that there had been no material changes in its R&D activities. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended December 31 were ¥13,089 million. There were no material changes in the status of the Group's R&D activities during the nine months ended December 31.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥4.426 billion. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company recorded R&D expenses of ¥4,426 million and explained that there had been no material changes in its R&D activities. - FY2018AdvancedAnnual report
「Regarding progress in fiscal 2017, in the Chemicals business we began selling an oil and fat decomposition treatment agent. In the Functional Materials business, covering displays, semiconductors, and inorganic materials, development progressed on high-quality, high-performance grades of existing products and new materials addressing customer needs and next-generation technologies.」
R&D expenses were ¥17.228 billion, with specific progress including the launch of sales of an oil and fat decomposition treatment agent, development of new materials, and development of agricultural chemical and pharmaceutical candidates. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the nine months of the current consolidated cumulative period were ¥12.399 billion. There were no material changes in the status of the group's R&D activities during the nine months of the current consolidated cumulative period.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the six months of the current consolidated cumulative period were ¥8.327 billion. There were no material changes in the status of the group's R&D activities during the six months of the current consolidated cumulative period.」
The company disclosed R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥4.022 billion. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company disclosed R&D expenses and explicitly stated that there were no material changes in the status of its R&D activities. - FY2017AdvancedAnnual report
「To strengthen our R&D capabilities in life sciences, we carried out comprehensive refurbishment work at the Biological Science Research Institute over six years from fiscal 2011 to fiscal 2016, completing the work this spring. We are also expanding our research infrastructure, including by developing a new research building at the Materials Science Research Institute.」
The company recorded R&D expenses of ¥16.078 billion and made specific progress in its research platform, including completion of refurbishment work at the Biological Science Research Institute and development of a new research building at the Materials Science Research Institute. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the nine months of the current consolidated cumulative period were ¥11.625 billion. There were no material changes in the status of the group's R&D activities during the nine months of the current consolidated cumulative period.」
The company disclosed R&D expenses for the cumulative period and stated that there were no material changes in the status of its R&D activities. - FY2017-Q1First statedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥4.073 billion. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company disclosed quarterly R&D expenses and indicated that there were no material changes in its R&D activities.